Skip to main content

Table 3 Responses by geographic area; p-values determined via chi-squared analysis with multiple group comparison

From: Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey

Survey Question

United States

Europe

Latin America

P-value

Yes (n (%))

No (n (%))

Yes (n (%))

No (n (%))

Yes (n (%))

No (n (%))

Statistical significance < 0.05

“Does your institution provide proper protection for all health care workers to the level they are exposed?”

759 (70.3%)

320 (29.7%)

58 (62.4%)

35 (37.6%)

104 (66.2%)

53 (33.8%)

0.168

“Have timely surgery/chemo/immunotherapy treatments for your patients been delayed since the COVID-19 pandemic started?”

565 (56.8%)

429 (432%)

44 (50%)

44 (50%)

87 (56.1%)

68 (43.9%)

0.009

“Do you use telemedicine to reduce in-person encounters and health care providers’ exposure?”

950 (88%)

129 (12%)

74 (81.3%)

17 (18.7%)

101 (63.9%)

57 (36.1%)

< 0.001

“Have you been asked to reduce your specialized practice to help/contribute to other areas where urgent help is needed?”

368 (34%)

713 (66%)

61 (65.6%)

32 (34.4%)

96 (61.5%)

60 (38.5%)

< 0.001

“Have you had in service instruction/guidelines from leadership at your institution about policies to protect your patients, your team, your colleagues and yourself?”

943 (86.7%)

145 (13.3%)

83 (89.2%)

10 (10.8%)

132 (84.1%)

25 (15.9%)

0.609

“Do you feel you have adequate support from your institution’s leadership to carry on with your duties?”

800 (74.1%)

279 (25.9%)

56 (60.2%)

37 (39.8%)

96 (61.9%)

59 (38.1%)

0.001

“Do you discuss with all your patients the importance of strict adherence to COVID-19 community behavior as part of your office/clinic encounters?”

978 (91.1%)

95 (8.9%)

87 (94.6%)

5 (5.4%)

152 (96.2%)

6 (3.8%)

0.035

“Do you have access to COVID-19 testing at your institution or local lab?”

812 (75%)

270 (25%)

62 (66.7%)

31 (33.3%)

84 (53.5%)

73 (46.5%)

< 0.001

“Has your institution used Tocilizumab or other anti-inflammatory agents for COVID-19 related myocarditis?”

156 (16.9%)

768 (83.1%)

10 (11.6%)

76 (88.4%)

14 (9%)

141 (91%)

< 0.001

Has your institution used empiric treatment with Remdesivir or other anti-viral treatments for the sickest patients?

323 (33.8%)

632 (66.2%)

18 (20.7%)

69 (79.3%)

24 (15.4%)

132 (84.6%)

< 0.001

“In your opinion, should there be a government mandated nationwide quarantine/lock-down to slow down the propagation/transmission of COVID-19?”

910 (84.4%)

168 (15.6%)

84 (92.3%)

7 (7.7%)

142 (91.6%)

13 (8.4%)

0.152

“Should medical professional organizations take a more active role, and have more influence in official health care policy decisions during this major crisis?”

1035 (95.5%)

49 (4.5%)

88 (95.7%)

4 (4.3%)

147 (93.6%)

10 (6.4%)

0.765